MDS and Secondary AML Display Unique Patterns and Abundance of Aberrant DNA Methylation

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2009 Aug 5

PMID 19652201

Citations 159

Authors

Maria E Figueroa

Lucy Skrabanek

Yushan Li

Anchalee Jiemjit

Tamer E Fandy

Elisabeth Paietta

Hugo Fernandez

Martin S Tallman

John M Greally

Hetty Carraway

Jonathan D Licht

Steven D Gore

Ari Melnick

Affiliations

Soon will be listed here.

Abstract

Increasing evidence shows aberrant hypermethylation of genes occurring in and potentially contributing to pathogenesis of myeloid malignancies. Several of these diseases, such as myelodysplastic syndromes (MDSs), are responsive to DNA methyltransferase inhibitors. To determine the extent of promoter hypermethylation in such tumors, we compared the distribution of DNA methylation of 14 000 promoters in MDS and secondary acute myeloid leukemia (AML) patients enrolled in a phase 1 trial of 5-azacytidine and the histone deacetylase inhibitor entinostat against de novo AML patients and normal CD34(+) bone marrow cells. The MDS and secondary AML patients displayed more extensive aberrant DNA methylation involving thousands of genes than did the normal CD34(+) bone marrow cells or de novo AML blasts. Aberrant methylation in MDS and secondary AML tended to affect particular chromosomal regions, occurred more frequently in Alu-poor genes, and included prominent involvement of genes involved in the WNT and MAPK signaling pathways. DNA methylation was also measured at days 15 and 29 after the first treatment cycle. DNA methylation was reversed at day 15 in a uniform manner throughout the genome, and this effect persisted through day 29, even without continuous administration of the study drugs. This trial was registered at www.clinicaltrials.gov as J0443.

Citing Articles

Somatic mutations and DNA methylation identify a subgroup of poor prognosis within lower-risk myelodysplastic syndromes.

Rombaut D, Sandmann S, Tekath T, Crouch S, de Graaf A, Smith A Hemasphere. 2025; 9(1):e70073.

PMID: 39850648 PMC: 11754767. DOI: 10.1002/hem3.70073.

Epigenetics-targeted drugs: current paradigms and future challenges.

Dai W, Qiao X, Fang Y, Guo R, Bai P, Liu S Signal Transduct Target Ther. 2024; 9(1):332.

PMID: 39592582 PMC: 11627502. DOI: 10.1038/s41392-024-02039-0.

Development of MDS in Pediatric Patients with GATA2 Deficiency: Increased Histone Trimethylation and Deregulated Apoptosis as Potential Drivers of Transformation.

Schreiber F, Piontek G, Schneider-Kimoto Y, Schwarz-Furlan S, De Vito R, Locatelli F Cancers (Basel). 2023; 15(23).

PMID: 38067298 PMC: 10705137. DOI: 10.3390/cancers15235594.

Depletion of results in age-dependent changes in DNA methylation and gene expression in a zebrafish model of myelodysplastic syndrome.

Neelamraju Y, Gjini E, Chhangawala S, Fan H, He S, Jing C Front Hematol. 2023; 2.

PMID: 37937078 PMC: 10629367. DOI: 10.3389/frhem.2023.1235170.

Low-dose decitabine-intensified modified conditioning regimen alleviates aGVHD in AML/MDS patients treated with allogeneic hematopoietic stem cell transplantation.

Zhu J, Wang Q, Ren H, Dong Y, Yin Y, Wang Q Front Immunol. 2023; 14:1274492.

PMID: 37928518 PMC: 10623305. DOI: 10.3389/fimmu.2023.1274492.

References

Edgar R, Domrachev M, Lash A . Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2001; 30(1):207-10. PMC: 99122. DOI: 10.1093/nar/30.1.207. View

Griffiths E, Gore S . DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin Hematol. 2008; 45(1):23-30. PMC: 2234265. DOI: 10.1053/j.seminhematol.2007.11.007. View

Culhane A, Thioulouse J, Perriere G, Higgins D . MADE4: an R package for multivariate analysis of gene expression data. Bioinformatics. 2005; 21(11):2789-90. DOI: 10.1093/bioinformatics/bti394. View

Polak P, Domany E . Alu elements contain many binding sites for transcription factors and may play a role in regulation of developmental processes. BMC Genomics. 2006; 7:133. PMC: 1513395. DOI: 10.1186/1471-2164-7-133. View

Gore S, Baylin S, Sugar E, Carraway H, Miller C, Carducci M . Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 2006; 66(12):6361-9. DOI: 10.1158/0008-5472.CAN-06-0080. View

Brakensiek K, Langer F, Schlegelberger B, Kreipe H, Lehmann U . Hypermethylation of the suppressor of cytokine signalling-1 (SOCS-1) in myelodysplastic syndrome. Br J Haematol. 2005; 130(2):209-17. DOI: 10.1111/j.1365-2141.2005.05590.x. View

Aggerholm A, Holm M, Guldberg P, Olesen L, Hokland P . Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol. 2005; 76(1):23-32. DOI: 10.1111/j.1600-0609.2005.00559.x. View

Kuo H, Griffith J, Kreuzer K . 5-Azacytidine induced methyltransferase-DNA adducts block DNA replication in vivo. Cancer Res. 2007; 67(17):8248-54. DOI: 10.1158/0008-5472.CAN-07-1038. View

Fenaux P . Inhibitors of DNA methylation: beyond myelodysplastic syndromes. Nat Clin Pract Oncol. 2005; 2 Suppl 1:S36-44. DOI: 10.1038/ncponc0351. View

10.

Jiang Y, Dunbar A, Gondek L, Mohan S, Rataul M, OKeefe C . Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood. 2008; 113(6):1315-25. PMC: 2637194. DOI: 10.1182/blood-2008-06-163246. View

11.

Fenaux P, Mufti G, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A . Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009; 10(3):223-32. PMC: 4086808. DOI: 10.1016/S1470-2045(09)70003-8. View

12.

Thompson R, Reimers M, Khulan B, Gissot M, Richmond T, Chen Q . An analytical pipeline for genomic representations used for cytosine methylation studies. Bioinformatics. 2008; 24(9):1161-7. PMC: 5061929. DOI: 10.1093/bioinformatics/btn096. View

13.

Elemento O, Slonim N, Tavazoie S . A universal framework for regulatory element discovery across all genomes and data types. Mol Cell. 2007; 28(2):337-50. PMC: 2900317. DOI: 10.1016/j.molcel.2007.09.027. View

14.

Silverman L, Demakos E, Peterson B, Kornblith A, Holland J, Odchimar-Reissig R . Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002; 20(10):2429-40. DOI: 10.1200/JCO.2002.04.117. View

15.

Jones P, Baylin S . The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3(6):415-28. DOI: 10.1038/nrg816. View

16.

Plass C . Cancer epigenomics. Hum Mol Genet. 2002; 11(20):2479-88. DOI: 10.1093/hmg/11.20.2479. View

17.

Raj K, John A, Ho A, Chronis C, Khan S, Samuel J . CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia. 2007; 21(9):1937-44. DOI: 10.1038/sj.leu.2404796. View

18.

Christiansen D, Andersen M, Pedersen-Bjergaard J . Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia. 2003; 17(9):1813-9. DOI: 10.1038/sj.leu.2403054. View

19.

Zhu W, Hileman T, Ke Y, Wang P, Lu S, Duan W . 5-aza-2'-deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell proliferation. J Biol Chem. 2004; 279(15):15161-6. DOI: 10.1074/jbc.M311703200. View

20.

Tessema M, Langer F, Dingemann J, Ganser A, Kreipe H, Lehmann U . Aberrant methylation and impaired expression of the p15(INK4b) cell cycle regulatory gene in chronic myelomonocytic leukemia (CMML). Leukemia. 2003; 17(5):910-8. DOI: 10.1038/sj.leu.2402891. View